Lifecore Biomedical (LFCR) Stock: Buy, Sell, or Hold?
LFCR - Lifecore Biomedical, Inc. Common Stock
$4.12
0.03 (0.73%)
▲
5d:
-5.29%
30d:
-13.63%
90d:
-27.08%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 05, 2026
0d
Get Alerted When LFCR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: LFCR shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: LFCR shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: LFCR is currently trading at $4.12, which is considered oversold relative to its 30-day fair value range of $4.30 to $4.75.
Technical Outlook: Technically, LFCR is in a downtrend. The price is currently testing key support at $4.00. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: LFCR scores 39/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $6.75 (+63.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, LFCR is in a downtrend. The price is currently testing key support at $4.00. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: LFCR scores 39/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $6.75 (+63.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$4.30 -
$4.75
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
66.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (39/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 63.8% below Wall St target ($6.75)
- WARNING: Composite score 47/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$4.30 -
$4.75
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.42
(10.3%)
Support & Resistance Levels
Support Level
$4.00
Resistance Level
$4.80
Current Trend
Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.56
Wall Street Target
$6.75
(+63.8%)
Revenue Growth (YoY)
-3.8%
Profit Margin
-23.8%
Share & Embed Analysis
Last updated: September 12, 2026 11:12 PM ET
Data refreshes hourly during market hours. Next update: 12:12 AM
Data refreshes hourly during market hours. Next update: 12:12 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LFCR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$212 | 60 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 70 BUY |
|
INDV
Indivior PLC Ordinary Sh… |
STRONG BUY
7 analysts |
$49 | 69 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 46 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 47 HOLD |
